AR059216A1 - 11b-hidroxiandrosta-4-eno-3-onas - Google Patents
11b-hidroxiandrosta-4-eno-3-onasInfo
- Publication number
- AR059216A1 AR059216A1 ARP070100355A ARP070100355A AR059216A1 AR 059216 A1 AR059216 A1 AR 059216A1 AR P070100355 A ARP070100355 A AR P070100355A AR P070100355 A ARP070100355 A AR P070100355A AR 059216 A1 AR059216 A1 AR 059216A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- oco
- halogen
- aryl
- Prior art date
Links
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 17
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004122 cyclic group Chemical group 0.000 abstract 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- -1 -O-C1-10 alkyl Chemical group 0.000 abstract 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 abstract 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 abstract 1
- 229910004679 ONO2 Inorganic materials 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 229940037128 systemic glucocorticoids Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C07J71/0015—Oxiranes at position 9(11)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Los compuestos reivindicados son potentes glucocorticoides antiinflamatorios ya que poseen una union selectiva hacia el receptor glucocorticoide. Reivindicacion 1: 11beta-hidroxiandrosta-4-eno-3-ona, compuesto de la formula (1), y la sal fisiologicamente aceptable del mismo: ------ representa una union simple o doble y representa la configuracion alfa o beta. En donde: Z representa O o S; R1 representa hidrogeno o metilo que puede estar ya sea en la configuracion alfa o beta, o metileno; R2 y R3 son lo mismo, o difieren y cada uno independientemente representa hidrogeno, halogeno o un grupo metilo; R5 representa un grupo seleccionado de alquilo C1-10, cicloalquilo C3-13, -O-alquilo C1-10, arilo o anillo heterocíclico en donde el anillo o sistema de anillo se encuentra sustituido o no sustituido por uno o más de entre halogeno, -OH, alquilo C1-3, -O-alquilo C1-3, cicloalquilo C3-13; en donde los grupos alquilo o cicloalquilo pueden contener opcionalmente una o más no saturaciones y/o puede tener uno o más heteroátomos incorporados en el mismo y opcionalmente en cada caso tener uno o más átomos de hidrogeno reemplazados por halogeno, -OH, alquilo C1-3, -O-alquilo C1-3, cicloalquilo C3-13; y R4 representa porcion seleccionada de un grupo que consiste de A, B y C, con la salvedad de que cuando R4 representa la porcion (C), Z es S, en donde m1 es 1, 2 o 3; m2 es 0 o 1; m3 es 0 o1; n1 es 0, 1 o2; R6 representa un grupo seleccionado de alquilo C1-8, cicloalquilo C3-13, arilo y un radical heterocíclico, donde el anillo o sistema de anillo se encuentra no sustituido o sustituido por uno o más sustituyentes seleccionados de alquilo C1-8, cicloalquilo C3-13, halogeno, O-alquilo C1-8, O-cicloalquilo C3-13, OCO-alquilo C1-3, S(O)0-2)-alquilo C1-8, COO-alquilo C1-8, -OCO-O-alquilo C1-3, -OCO-CO-O-alquilo C1-3, CONH2, CONH-alquilo C1-8, CON-[(alquilo C1-8]2, -NHCO-alquilo C1-8, N-alquilo C1-8-CO-alquilo C1-8, -NHCO-O-alquilo C1-8, -N-alquilo C1-8- CO-O-alquilo C1-8, -NHCONH-alquilo C1-8, -N-alquilo C1-8-CONH-alquilo C1-8, -NHCONH-SO2-alquilo C1-8, -N-alquilo C1-8-CONH-SO2-alquilo C1-8, -NO2, -CN; en donde los grupos alquilo o cicloalquilo pueden contener opcionalmente una o más no saturaciones y/o pueden tener uno o más heteroátomos incorporados en el mismo y opcionalmente, en cada caso tener uno o más átomos de hidrogeno reemplazados por halogeno, -OH, alquilo C1-3, -OCO-alquilo C1-3 o cicloalquilo C3-13; con la salvedad de que cuando R4 representa la porcion A en donde R6 representa cicloalquilo C3-13 opcionalmente conteniendo uno o más heteroátomos incorporados en el mismo, el heteroátomo no es nitrogeno; P y Q se seleccionan independientemente de hidrogeno y alquilo C1-3, o P y Q pueden unirse con el átomo de carbono al cual se encuentran anexos para formar cicloalquilo C3-8 como se representa en la porcion (A-1) en donde m1 es 1 y n2 es 0,1, 2, 3, 4 o 5 y R6 es un arilo como se define precedentemente; o P y R6 pueden unirse para formar un sistema cíclico como lo representa la porcion (A-2), en donde m1 es 1 y n2 es 0, 1, 2 3 o 4 y el anillo G es un arilo como se define precedentemente; X representa una union doble o triple; J, K y L se seleccionan independientemente del un grupo que consiste de hidrogeno, halogeno, alquilo C1-10, cicloalquilo C3-13, -OH, -O-alquilo C1-10, O-cicloalquilo C3-13, -OCO-alquilo C1-10, -OCO-cicloalquilo C3-13, -OCO-CO-O-alquilo C1-10, -OCO-CO-O-icloalquilo C3-13, - OCO-O-alquilo C1-10, -OCO-O-cicloalquilo C3-13, -OCO-NH-alquilo C1-10, -OCO-NH-cicloalquilo C3-13, -OCO-N-[(alquilo C1-10)]2, -OCO-N-[(cicloalquilo C3-13)]2, -OCO-NHSO2-alquilo C1-10, - OCO- NHSO2-cicloalquilo C3-13, -NH2, -NH-alquilo C1-8, -N- [(alquilo C1-18)]2, -NO2 y -CN; en donde los grupos alquilo o cicloalquilo pueden contener opcionalmente una o más no saturaciones y/o pueden tener uno o más heteroátomos incorporados en el mismo y opcionalmente, en cada caso tener uno o más átomos de hidrogeno reemplazados por halogeno, -OH, alquilo C1-3, -O-alquilo C1-3, -OCO-alquilo C1-3, -COOH, -COO-alquilo C1-5, -COO-haloalquilo C1-5, -NHCO-alquilo C1-8, -ONO2, -NH-alquilo C1-8, -N-[(alquilo C1-8)]2, -NO2, -CN, cicloalquilo C3-13, arilo o radical heterocíclico; o J y K pueden unirse con el átomo de carbono al cual se anexan para representar un grupo cicloalquilo C3-13 o -CO- y L es lo definido precedentemente; o J, K y L están ausentes cuando n1 es 0; R7 representa un grupo seleccionado de hidrogeno, halogeno, arilo y CO-arilo, en donde el anillo o sistema de anillo se encuentra no sustituido o sustituido como se define precedentemente; o R7, representa la porcion (C-1), en donde n1, J, K y L son lo definido precedentemente, X representa una union simple, doble o triple, m2 es 0, 1 o 2 y m3 es 0, 1 o 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN131MU2006 | 2006-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059216A1 true AR059216A1 (es) | 2008-03-19 |
Family
ID=38459436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100355A AR059216A1 (es) | 2006-01-27 | 2007-01-26 | 11b-hidroxiandrosta-4-eno-3-onas |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8785425B2 (es) |
| EP (1) | EP2004667B1 (es) |
| JP (1) | JP5097129B2 (es) |
| KR (1) | KR101390272B1 (es) |
| CN (1) | CN101384610B (es) |
| AP (1) | AP2642A (es) |
| AR (1) | AR059216A1 (es) |
| AU (1) | AU2007220114B2 (es) |
| BR (1) | BRPI0706767A2 (es) |
| CA (1) | CA2637548C (es) |
| EA (1) | EA017490B9 (es) |
| EC (1) | ECSP088689A (es) |
| ES (1) | ES2428066T3 (es) |
| IL (1) | IL192983A (es) |
| MX (1) | MX2008009173A (es) |
| NZ (1) | NZ569867A (es) |
| SG (1) | SG170049A1 (es) |
| TW (1) | TWI374147B (es) |
| UA (1) | UA95095C2 (es) |
| WO (1) | WO2007099548A2 (es) |
| ZA (1) | ZA200806366B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR059216A1 (es) | 2006-01-27 | 2008-03-19 | Sun Pharmaceutical Ind Ltd | 11b-hidroxiandrosta-4-eno-3-onas |
| WO2007144668A2 (en) * | 2006-06-14 | 2007-12-21 | Generics [Uk] Limited | Process for the preparation of s-fluoromethyl-6, 9 -difluoro-11 -hydroxy-16 -methyl-17-propionyloxy-3-oxo-androsta-1,4-diene-17 -carbothioate and intermediates |
| AU2013202843B2 (en) * | 2006-06-14 | 2015-11-12 | Generics [Uk] Limited | Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1, 4-diene-17-carbothioate and intermediates |
| CA2760284A1 (en) | 2009-05-29 | 2010-12-02 | Pfizer Limited | Novel glucocorticoid receptor agonists |
| WO2011132171A1 (en) | 2010-04-23 | 2011-10-27 | Piramal Life Sciences Limited | Nitric oxide releasing prodrugs of therapeutic agents |
| KR101103943B1 (ko) * | 2011-12-12 | 2012-01-12 | 오수련 | 무료이용쿠폰을 활용한 제휴사 및 리셀러의 온라인 제휴마케팅 운영방법 |
| WO2013133980A1 (en) * | 2012-03-05 | 2013-09-12 | Bausch & Lomb Incorporated | Nitroxy derivatives of soft steroids |
| US9844599B2 (en) | 2013-01-21 | 2017-12-19 | Apparao Satyam | Nitric oxide releasing produgs of therapeutic agents |
| KR20160030085A (ko) * | 2013-05-28 | 2016-03-16 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | S-[4-(3-플루오로-3-메틸부티릴옥시)부트-2-인일]6α,9α-디플루오로-17α-(푸란-2-일)카보닐옥시-11β-히드록시-16α-메틸-3-옥소안드로스타-1,4-디엔-17β-카보티오에이트를 사용한 염증성 병태의 치료 방법 |
| EA201791741A1 (ru) * | 2015-01-31 | 2017-12-29 | Сан Фарма Адвансед Ресёрч Компани Лимитед | КРИСТАЛЛИЧЕСКАЯ ФОРМА S-[4-(3-ФТОР-3-МЕТИЛБУТИРИЛОКСИ)БУТ-2-ИНИЛ]-6α,9α-ДИФТОР-17α-(ФУРАН-2-ИЛ)КАРБОНИЛОКСИ-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСОАНДРОСТА-1,4-ДИЕН-17β-КАРБОТИОАТА |
| CN106279341A (zh) * | 2015-05-11 | 2017-01-04 | 正大天晴药业集团股份有限公司 | 一种糠酸氟替卡松的制备方法 |
| CN109438543B (zh) * | 2018-11-28 | 2020-09-15 | 广州健康元呼吸药物工程技术有限公司 | 一种高纯度糠酸氟替卡松的制备方法 |
| CN111662353A (zh) * | 2019-03-05 | 2020-09-15 | 上海谷森医药有限公司 | 一种糠酸氟替卡松晶型1的制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US392976A (en) * | 1888-11-13 | Support for spinning-spindles | ||
| US300792A (en) * | 1884-06-24 | John asbeeey nicholson | ||
| US3007923A (en) | 1959-01-22 | 1961-11-07 | Lab Francais Chimiotherapie | Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids |
| SE378109B (es) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US4188385A (en) * | 1978-04-05 | 1980-02-12 | Syntex (U.S.A.) Inc. | Thioetianic acid derivatives |
| CA1201114A (en) | 1980-02-15 | 1986-02-25 | Gordon H. Phillipps | Androstane carbothioates |
| SE449106B (sv) * | 1980-07-10 | 1987-04-06 | Otsuka Pharma Co Ltd | Steroid med anti-inflammatorisk verkan samt komposition innehallande denna |
| US4996335A (en) * | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| ZA814440B (en) * | 1980-07-10 | 1982-10-27 | Otsuka Pharma Co Ltd | Soft steroids having anti-inflammatory activity |
| US6610675B1 (en) * | 1980-07-10 | 2003-08-26 | Nicholas S. Bodor | Inactive metabolite approach to soft drug design |
| DE3260474D1 (en) | 1981-02-02 | 1984-09-06 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
| US6197761B1 (en) * | 1995-12-29 | 2001-03-06 | Glaxo Wellcome Inc. | 17β-2-oxo-tetrahydrofuranyl)-carbothioic acid ester, -carboxylic acid ester and -carboxylic acid amide androstane derivatives |
| US5981517A (en) * | 1996-05-09 | 1999-11-09 | Soft Drugs, Inc. | Androstene derivatives |
| EP0998484B1 (en) | 1997-06-30 | 2004-03-03 | Glaxo Group Limited | Method of identifying compounds having reduced systemic effects |
| GB0125259D0 (en) * | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| US7208613B2 (en) * | 2002-06-20 | 2007-04-24 | Sun Pharmaceutical Industries Limited | Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate |
| GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| AR059216A1 (es) | 2006-01-27 | 2008-03-19 | Sun Pharmaceutical Ind Ltd | 11b-hidroxiandrosta-4-eno-3-onas |
-
2007
- 2007-01-26 AR ARP070100355A patent/AR059216A1/es not_active Application Discontinuation
- 2007-01-26 TW TW096103094A patent/TWI374147B/zh not_active IP Right Cessation
- 2007-01-29 SG SG201101431-3A patent/SG170049A1/en unknown
- 2007-01-29 EP EP07736511.2A patent/EP2004667B1/en not_active Not-in-force
- 2007-01-29 AU AU2007220114A patent/AU2007220114B2/en not_active Ceased
- 2007-01-29 WO PCT/IN2007/000039 patent/WO2007099548A2/en not_active Ceased
- 2007-01-29 CA CA2637548A patent/CA2637548C/en not_active Expired - Fee Related
- 2007-01-29 UA UAA200809718A patent/UA95095C2/ru unknown
- 2007-01-29 NZ NZ569867A patent/NZ569867A/xx not_active IP Right Cessation
- 2007-01-29 JP JP2008551960A patent/JP5097129B2/ja not_active Expired - Fee Related
- 2007-01-29 MX MX2008009173A patent/MX2008009173A/es active IP Right Grant
- 2007-01-29 KR KR1020087020127A patent/KR101390272B1/ko not_active Expired - Fee Related
- 2007-01-29 EA EA200801596A patent/EA017490B9/ru not_active IP Right Cessation
- 2007-01-29 CN CN2007800036603A patent/CN101384610B/zh not_active Expired - Fee Related
- 2007-01-29 BR BRPI0706767-4A patent/BRPI0706767A2/pt not_active IP Right Cessation
- 2007-01-29 ES ES07736511T patent/ES2428066T3/es active Active
- 2007-01-29 AP AP2008004558A patent/AP2642A/xx active
-
2008
- 2008-07-22 IL IL192983A patent/IL192983A/en not_active IP Right Cessation
- 2008-07-22 ZA ZA200806366A patent/ZA200806366B/xx unknown
- 2008-07-25 US US12/180,257 patent/US8785425B2/en not_active Expired - Fee Related
- 2008-08-21 EC EC2008008689A patent/ECSP088689A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059216A1 (es) | 11b-hidroxiandrosta-4-eno-3-onas | |
| NI201000130A (es) | Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica. | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| CO6300864A2 (es) | Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
| PE20080524A1 (es) | DERIVADOS DE 1H-IMIDAZO[4,5-b]PIRAZIN Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
| AR039665A1 (es) | Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa | |
| CO6241101A2 (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
| AR094704A1 (es) | Compuestos y composiciones como degradantes selectivos del receptor de estrógeno | |
| AR069814A1 (es) | Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen | |
| ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| CO6321230A2 (es) | Compuesto espiro, una sal aceptable para uso farmaceutico y un solvato del mismo y composicion farmaceutica que lo contenga | |
| PE20090511A1 (es) | Imidazopiridinonas | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR045234A1 (es) | Metodo para producir derivados del almidon de hidroxialquilo y composiciones farmaceuticas que los contienen. | |
| CO6190521A2 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta -9 desaturasa | |
| AR052343A1 (es) | Analogos de tetrahidroquinolina como agonistas muscarinicos | |
| AR069480A1 (es) | Derivados de 2-amino-pirimidina | |
| CR11220A (es) | Derivados de pirimidina 934 | |
| CO6300861A2 (es) | Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| CO6150150A2 (es) | Derivados de 7-alquinil-1,8-naftiridonas su prepacion y su aplicacion en terapeutica | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| AR095708A1 (es) | Indazoles sustituidos con diaminoheteroarilo | |
| AR058381A1 (es) | Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |